5-Hydroxy-1-methylhydantoin

Research use only, not for human use.

NZ-419 is an antioxidant potentially for the treatment of renal failure.

NZ-419 is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, NZ-419, a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. NZ-419 a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. NZ-419 inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that NZ-419 may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties.

——

——

NZ-419 | HD-003

GPCR/G Protein

Bradykinin Receptor

——

——

——

84210-26-4

114.1

C4H6N2O2

>98% (HPLC)

——

O=C1NC(CN1C)=O

——

(-20℃)

With Ice Pack

≥ 2 years